Boldine Ameliorates Estrogen Deficiency-Induced Bone Loss via Inhibiting Bone Resorption

Frontiers in Pharmacology

Shuang Liang¹  Yu-ting Wang¹  Hui Liu¹  Peng Cheng¹  An-min Chen¹  Kun Chen²  Virginia-Jeni Akila Parkman²  Chen-he Zhou³  Hui Lin⁴  Wen-tao Zhu⁵  Zheng-tao Lv⁵  Qing Yang⁵  Hui Liao⁵  Xing-zhi Jing⁵ 

[1] Biological Engineering and Regenerative Medicine Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China;Department of Oral Medicine, Infection, and Immunity, Harvard School of Dental Medicine, Boston, MA, United States;Department of Orthopaedic Surgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China;Department of Orthopaedic Surgery, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China;Department of Orthopedics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China;

关键词: boldine;    osteoporosis;    osteoclast;    osteoblast;    AKT;   

DOI  :  10.3389/fphar.2018.01046

来源: DOAJ

【 摘 要 】

Osteoporosis is an enormous health problem caused by the imbalance between bone resorption and bone formation. The current therapeutic strategies for osteoporosis still have some limitations. Boldine, an alkaloid isolated from Peumus boldus, has been shown to have antioxidant and anti-inflammatory effects in vivo. For the first time, we discover that boldine has a protective effect for the estrogen deficiency-induced bone loss in mice. According to the Micro-CT and histomorphometry assays, boldine conducts this protective effect through inhibiting bone resorption without affecting bone formation in vivo. Moreover, we showed that boldine can inhibit receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation via impairing the AKT signaling pathways, while SC79 (an AKT agonist) partially rescue this effect. In conclusion, our results suggest that boldine can prevent estrogen deficiency-induced osteoporosis by inhibiting osteoclastogenesis. Thus, boldine may be served as a novel therapeutic agent for anti-osteoporotic therapy.

【 授权许可】

Unknown